PAK1 and metastatic neoplasm: Our findings suggest that despite the presence of OS in the lymphohematogenous circulation, PAK1‐specific therapy may still have a potential clinical benefit by reducing the progression of pulmonary metastases and the development of the clinically overt metastatic disease.